Needham

Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares

Retrieved on: 
Thursday, March 30, 2023

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the pricing of an underwritten public offering of 10,000,001 of its ordinary shares, nominal value $0.01 per share (“Ordinary Shares”) in the form of American Depositary Shares (“ADSs”) and of 4,705,882 Series B Non-Voting Convertible Preferred Shares, convertible into Ordinary Shares on a one-for-one basis (the “Preferred Shares,” together with the ADSs, the “Shares”).

Key Points: 
  • DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the pricing of an underwritten public offering of 10,000,001 of its ordinary shares, nominal value $0.01 per share (“Ordinary Shares”) in the form of American Depositary Shares (“ADSs”) and of 4,705,882 Series B Non-Voting Convertible Preferred Shares, convertible into Ordinary Shares on a one-for-one basis (the “Preferred Shares,” together with the ADSs, the “Shares”).
  • The public offering price of each ADS is $8.50 and the public offering price of each Preferred Share is $8.50.
  • In connection with the public offering, Avadel has granted the underwriters a 30-day option to purchase up to an additional 2,205,882 ADSs at the public offering price, less the underwriting discounts and commissions.
  • The gross proceeds to Avadel from the offering are expected to be approximately $125 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering of ADSs and Series B Preferred Shares

Retrieved on: 
Wednesday, March 29, 2023

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is commencing an underwritten public offering of its ordinary shares, nominal value $0.01 per share (“Ordinary Shares”) in the form of American Depositary Shares (“ADSs”).

Key Points: 
  • DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is commencing an underwritten public offering of its ordinary shares, nominal value $0.01 per share (“Ordinary Shares”) in the form of American Depositary Shares (“ADSs”).
  • Avadel may, in lieu of ADSs, offer and sell to certain investors Series B Non-Voting Convertible Preferred Shares, convertible into Ordinary Shares on a one-for-one basis (the “Preferred Shares,” together with the ADSs, the “Shares”).
  • All of the Shares are being offered by Avadel.
  • In connection with the offering, Avadel intends to grant the underwriters a 30-day option to purchase additional ADSs at the public offering price, less the underwriting discounts and commissions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surmodics, Inc. - SRDX

Retrieved on: 
Wednesday, March 1, 2023

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Surmodics, Inc. (“Surmodics” or the “Company”) (NASDAQ: SRDX).

Key Points: 
  • NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Surmodics, Inc. (“Surmodics” or the “Company”) (NASDAQ: SRDX).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Surmodics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

Harris Williams Names Martin Keck as Managing Director, Technology Group

Retrieved on: 
Tuesday, February 21, 2023

Harris Williams, a global investment bank specializing in M&A advisory services, today announced that Martin Keck has joined the firm’s Boston office as a managing director in the Technology Group.

Key Points: 
  • Harris Williams, a global investment bank specializing in M&A advisory services, today announced that Martin Keck has joined the firm’s Boston office as a managing director in the Technology Group.
  • Mr. Keck was most recently a managing director at Needham & Company and brings nearly 20 years of advisory experience to Harris Williams, including sector-specific expertise across education technology, HR and talent technology, and non-profit software.
  • “We are pleased to welcome Martin to Harris Williams as we continue to grow our technology practice,” said Bob Baltimore and John Neuner, co-CEOs of Harris Williams.
  • “Martin is a thoughtful and trusted M&A advisor who has deep experience and expertise in key technology verticals.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surmodics, Inc. - SRDX

Retrieved on: 
Monday, February 20, 2023

NEW YORK, Feb. 20, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Surmodics, Inc. (“Surmodics” or the “Company”) (NASDAQ: SRDX).

Key Points: 
  • NEW YORK, Feb. 20, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Surmodics, Inc. (“Surmodics” or the “Company”) (NASDAQ: SRDX).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Surmodics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Surmodics, Inc. – SRDX

Retrieved on: 
Thursday, February 16, 2023

NEW YORK, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Surmodics, Inc. (“Surmodics” or the “Company”) (NASDAQ: SRDX).

Key Points: 
  • NEW YORK, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Surmodics, Inc. (“Surmodics” or the “Company”) (NASDAQ: SRDX).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Surmodics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

Paragon 28, Inc. Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Retrieved on: 
Friday, February 17, 2023

562,500 shares were sold by Paragon and 412,500 shares were sold by certain selling securityholders.

Key Points: 
  • 562,500 shares were sold by Paragon and 412,500 shares were sold by certain selling securityholders.
  • After giving effect to the sale of these additional shares, a total of 4,312,500 shares were sold by Paragon and 3,162,500 shares were sold by the selling securityholders in the offering.
  • Paragon received aggregate gross proceeds of approximately $73.3 million in the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Paragon.
  • Paragon did not receive any proceeds from the sale of common stock by the selling securityholders.

Paragon 28, Inc. Announces Pricing of Public Offering

Retrieved on: 
Thursday, January 26, 2023

Paragon 28, Inc. (NYSE: FNA) (“Paragon”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the pricing of the previously announced underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $17.00 per share, before underwriting discounts and commissions.

Key Points: 
  • Paragon 28, Inc. (NYSE: FNA) (“Paragon”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the pricing of the previously announced underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $17.00 per share, before underwriting discounts and commissions.
  • 3,750,000 shares in the offering are being offered for sale by Paragon and 2,750,000 shares are being offered for sale by certain selling securityholders.
  • The gross proceeds from the offering to Paragon are expected to be approximately $63.8 million.
  • Paragon intends to use the net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by Paragon, for working capital, capital expenditures and other general corporate purposes.

Paragon 28, Inc. Announces Proposed Public Offering of Common Stock

Retrieved on: 
Wednesday, January 25, 2023

Paragon and the selling securityholders also expect to grant the underwriters a 30-day option to purchase up to an additional 562,500 and 412,500 shares of common stock, respectively.

Key Points: 
  • Paragon and the selling securityholders also expect to grant the underwriters a 30-day option to purchase up to an additional 562,500 and 412,500 shares of common stock, respectively.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Paragon intends to use the net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by Paragon, for working capital, capital expenditures and other general corporate purposes.
  • Paragon will not receive any proceeds from the sale of common stock offered by the selling securityholders.

Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million

Retrieved on: 
Tuesday, January 10, 2023

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its upsized underwritten public offering of common stock and pre-funded warrants, plus the full exercise of the underwriters’ option to purchase additional shares of common stock for total gross proceeds of $227.8 million.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its upsized underwritten public offering of common stock and pre-funded warrants, plus the full exercise of the underwriters’ option to purchase additional shares of common stock for total gross proceeds of $227.8 million.
  • All of the securities in the offering were sold by Geron.
  • The estimated net proceeds to Geron from this underwritten public offering, after deducting the underwriting discount and other estimated offering expenses, are approximately $213.3 million.
  • Geron intends to use the remaining proceeds, if any, for working capital and general corporate purposes.